A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)

Abstract

There was no significant difference in the proportion of patients alive and free of respiratory failure at Day 28. However, despite the lack of clinical benefit, a reduction in inflammatory markers was observed with otilimab, in addition to an acceptable safety profile.